April 30, 2020

Clinical Reports

  • Pulmonary Embolism and Increased Levels of d-Dimer in Patients with Coronavirus Disease
    Authors report 3 patients with coronavirus disease who had a decline in respiratory status during their hospital course that responded well to intravenous steroids and interleukin-6 receptor antagonist therapy. These patients later showed development of persistent hypoxia with increased levels of d-dimer levels and were given a diagnosis of pulmonary embolisms.

Antiviral Therapeutics & Vaccines

  • Adaptive COVID-19 Treatment Trial “ACTT” (NIAID)

    RESULTS (N=1063)

    • Primary Endpoint: Median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo (p<0.001)
    • Mortality rate of 8.0% for the group receiving remdesivir versus 11.6% for the placebo group (NS, p=0.059) 
  • SIMPLE I Trial results (Gilead)

    RESULTS (N~400)

    • Similar improvement in clinical status for 5-day course vs 10-day course of treatment

    No placebo control

  • Remdesivir in Chinese adults with severe COVID-19

    RESULTS (237 patients were enrolled and randomly assigned to a treatment group; 158 to remdesivir and 79 to placebo)

    • Stopped prior to full enrollment due to slow patient enrollment
    • Remdesivir use was not associated with a difference in time to clinical improvement (hazard ratio 1·23 [95% CI 0·87–1·75]).
    • Mortality 14% Remdesivir, 13% placebo
    • Remdesivir did not result in significant reductions in SARS-CoV-2 RNA loads compared to placebo in upper respiratory tract or sputum specimens


Situation Dashboards


World Health Organization (WHO)

Novel Coronavirus (COVID-19) Situation from World Health Organization (WHO)

Johns Hopkins University (JHU)

Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at JHU

COVID-19 in US and Canada

1Point3Acres Real-Time Coronavirus (COVID-19) Updates in US and Canada with Credible Sources

Genomic Epidemiology COVID-19

Genomic Epidemiology of (COVID-19) Maintained by the Nextstrain team, enabled by data from GISAID.

Sources for COVID-19 Information


World Health Organization (WHO)


Centers for Disease Control, US


International Society for Infectious Diseases


This Week in Virology (TWIV)

Receive updates about Parasites without Borders initiatives, developments, and learn more about parasites by subscribing to our periodic newsletter.

Parasites Without Borders

A comprehensive educational resource on all aspects of parasitic diseases and their impact on humanity around the globe.

Donate to Parasites Without Borders today!

Help bring the latest medical and basic biological information pertaining to diseases caused by eukaryotic parasites to every practicing physician and medical student within the United States.

Scroll to Top